

Article

Survival Rates of Patients with Non-Small Cell Lung Cancer Depending on Lymph Node Metastasis: A Focus on Saliva

Lyudmila V. Bel'skaya ^{1,*}, Elena A. Sarf ¹ and Victor K. Kosenok ²

¹ Biochemistry Research Laboratory, Omsk State Pedagogical University, 644099 Omsk, Russia; nem-cha@mail.ru

² Department of Oncology, Omsk State Medical University, 644099 Omsk, Russia; victorkosenok@gmail.com

* Correspondence: ludab2005@mail.ru and belskaya@omgpu.ru

Table S1. Characteristics of cohorts depending on the differences in the chemical composition of saliva in pNo.

LNS	Variables	Favorable Prognosis	Unfavorable Prognosis
pNo		LDH	
	LDH, U/L	>1294	<1294
	Age, years	61.8±1.93	60.3±1.86
	Gender	M—45, F—15	M—52, F—8
	pT	pT1—9, pT2—42, pT3—9	pT1—9, pT2—38, pT3—13
	Histological subtype	ADC—37, SCC—23	ADC—38, SCC—22
	Morphological growth forms	Peripheral—56, central—4	Peripheral—50, central—10
	Treatment type	Radical—37, combined—20	Radical—42, combined—16
	Smoking status	Smokers—27, non-smokers—33	Smokers—26, non-smokers—34
	Relapse status	Yes—13, no—47	Yes—20, no—40
pNo		DC	
	DC, c.u.	<3.97	>3.97
	Age, years	59.7±1.95	62.1±1.82
	Gender	M—44, F—12	M—53, F—11
	pT	pT1—9, pT2—37, pT3—10	pT1—9, pT2—43, pT3—12
	Histological subtype	ADC—36, SCC—20	ADC—39, SCC—25
	Morphological growth forms	Peripheral—49, central—7	Peripheral—57, central—6
	Treatment type	Radical—35, combined—20	Radical—44, combined—16
	Smoking status	Smokers—21, non-smokers—35	Smokers—32, non-smokers—32
	Relapse status	Yes—13, no—43	Yes—20, no—44
pNo		LDH + DC	
	LDH + DC	>1294, <3.97	<1294, >3.97
	Age, years	61.2±2.37	61.9±2.13
	Gender	M—23, F—7	M—31, F—3
	pT	pT1—5, pT2—19, pT3—6	pT1—5, pT2—20, pT3—9
	Histological subtype	ADC—17, SCC—13	ADC—19, SCC—15
	Morphological growth forms	Peripheral—27, central—3	Peripheral—29, central—5
	Treatment type	Radical—16, combined—13	Radical—23, combined—9
	Smoking status	Smokers—11, non-smokers—19	Smokers—16, non-smokers—18
	Relapse status	Yes—5, no—25 *	Yes—12, no—22

Note. *—differences are statistically significant, $p < 0.05$; ADC—adenocarcinoma, SCC—squamous cell carcinoma; M—male, F—female. LNS—lymph node status. LDH—lactate dehydrogenase, DC—diene conjugates.

Table S2. Characteristics of cohorts depending on the differences in the chemical composition of saliva in pN₁.

LNS	Variables	Favorable Prognosis	Unfavorable Prognosis
		ICs	
pN ₁	ICs, mmol/L	<0.296	>0.296
	Age, years	59.8±2.49	60.4±3.31
	Gender	M—21, F—4	M—24, F—2
	pT	pT2—11, pT3—13, pT4—1	pT2—9, pT3—10, pT4—7
	Histological subtype	ADC—11, SCC—14	ADC—11, SCC—15
	Morphological growth forms	Peripheral—15, central—10	Peripheral—12, central—13
	Treatment type	Radical—3, combined—14, palliative—6	Radical—0, combined—13, palliative—13
	Smoking status	Smokers—12, non-smokers—13	Smokers—16, non-smokers—10
	Relapse status	Yes—16, no—9	Yes—16, no—10
MM			
pN ₁	MM, c.u.	>0.903	<0.903
	Age, years	60.4±2.77	59.8±3.11
	Gender	M—22, F—4	M—23, F—2
	pT	pT2—9, pT3—14, pT4—3	pT2—11, pT3—9, pT4—5
	Histological subtype	ADC—10, SCC—16	ADC—12, SCC—13
	Morphological growth forms	Peripheral—14, central—12	Peripheral—14, central—11
	Treatment type	Radical—2, combined—14, palliative—9	Radical—1, combined—13, palliative—10
	Smoking status	Smokers—11, non-smokers—15	Smokers—17, non-smokers—8
	Relapse status	Yes—17, no—9	Yes—15, no—10
ICs + MM			
pN ₁	ICs + MM	< 0.296, > 0.903	> 0.296, < 0.903
	Age, years	61.1±3.46	61.2±4.66
	Gender	M—13, F—2	M—15, F—0
	pT	pT2—5, pT3—9, pT4—1	pT2—5, pT3—5, pT4—5
	Histological subtype	ADC—6, SCC—9	ADC—7, SCC—8
	Morphological growth forms	Peripheral—9, central—6	Peripheral—8, central—7
	Treatment type	Radical—2, combined—8, palliative—4	Radical—0, combined—7, palliative—8
	Smoking status	Smokers—6, non-smokers—9	Smokers—11, non-smokers—4
	Relapse status	Yes—9, no—6	Yes—8, no—7

Note. ADC—adenocarcinoma, SCC—squamous cell carcinoma; M—male, F—female. LNS—lymph node status. ICs—imidazole compounds, MM—middle molecular toxins.

Table S3. Characteristics of cohorts depending on the differences in the chemical composition of saliva in pN₂.

LNS	Variables	Favorable prognosis	Unfavorable prognosis
		Protein	
pN ₂	Protein, g/L	>0.583	<0.583
	Age, years	59.1±3.04	58.2±2.52
	Gender	M—27, F—6	M—27, F—7
	pT	pT3—16, pT4—17	pT3—20, pT4—14
	Histological subtype	ADC—16, SCC—17	ADC—17, SCC—17
	Morphological growth forms	Peripheral—16, central—16, mediastinal—1	Peripheral—16, central—16, mediastinal—2
	Treatment type	Radical—3, combined—9, palliative—18	Radical—2, combined—10, palliative—17
	Smoking status	Smokers—13, non-smokers—20	Smokers—17, non-smokers—17
	Relapse status	Yes—22, no—11	Yes—18, no—16
pN ₂	SB		
	SB, c.u.	< 0.602	> 0.602
	Age, years	59.0±2.87	59.1±2.67
	Gender	M—27, F—7	M—28, F—6
	pT	pT3—21, pT4—13	pT3—15, pT4—19
	Histological subtype	ADC—18, SCC—16	ADC—12, SCC—13
	Morphological growth forms	Peripheral—16, central—16, mediastinal—2	Peripheral—17, central—16, mediastinal—1
	Treatment type	Radical—2, combined—10, palliative—19	Radical—3, combined—9, palliative—17
	Smoking status	Smokers—15, non-smokers—19	Smokers—16, non-smokers—18
	Relapse status	Yes—19, no—15	Yes—22, no—12
pN ₂	Protein + SB		
	Protein + SB	> 0.583 + > 0.602; < 0.583 + < 0.602	< 0.583 + > 0.602; > 0.583 + < 0.602
	Age, years	58.6±2.59	59.3±4.66
	Gender	M—28, F—7	M—26, F—6
	pT	pT3—21, pT4—14	pT3—15, pT4—17
	Histological subtype	ADC—14, SCC—21	ADC—19, SCC—13
	Morphological growth forms	Peripheral—16, central—18, mediastinal—1	Peripheral—16, central—14, mediastinal—2
	Treatment type	Radical—3, combined—13, palliative—15	Radical—2, combined—6, palliative—20
	Smoking status	Smokers—14, non-smokers—21	Smokers—16, non-smokers—16
	Relapse status	Yes—21, no—14	Yes—19, no—13

Note. $p < 0.05$; ADC—adenocarcinoma, SCC—squamous cell carcinoma; M—male, F—female. LNS—lymph node status. SB—Schiff bases.